Our Products


48-49 Russell Square, London, WC1B 4JP UK

T: +44 (0)203 0084416

E: info@valirx.com

Val 201

ValiPharma is in late pre-clinical evaluation stages of a novel peptide for the treatment of refractory prostate cancer and other hormone-induced growth abnormalities, including breast and ovarian cancer and endometriosis.

Although androgen withdrawal can control prostate cancer for long periods, there remains a substantial unmet clinical need when faced with patients whose tumour becomes androgen independent. Many of these patients rapidly develop hormone refractory and metastatic prostate cancer. The prognosis for these patients is very poor – less than 50% survive beyond 2 years. VAL201 selectively inhibits androgen, oestrogen and epithelial growth factor dependent DNA synthesis. In pre-clinical studies carried out in collaboration with the University of Oxford, VAL201 prevented cancerous growth in live models; the response has been shown to be dose dependent.

Furthermore, the treated models remained fertile and produced normal offspring. In contrast to traditional therapies, VAL201 appears to leave other hormone induced activities working normally, therefore reducing side effects such as lowered sexual function and infertility. As such, VAL201 also shows promise for superior therapeutics for the treatment of hormone induced noncancerous cell growth as seen in endometriosis.

ValiPharma is progressing the final stages of VAL201’s preclinical programme to support the regulatory requirements prior to entering clinical trials.

test tubes